Form 4: Agios CFO Sells Shares for Tax After RSU Vesting

Agios Pharmaceuticals' CFO, Cecilia Jones, reported the acquisition of common stock from RSU vesting and a subsequent sale to cover tax obligations.

Summary

• Cecilia Jones, Chief Financial Officer of Agios Pharmaceuticals, Inc. (AGIO), reported transactions on September 26, 2025.
• Acquired 7,472 shares of common stock at a price of $0, resulting from the vesting of restricted stock units.
• Disposed of 3,651 shares of common stock at a price of $36.77 per share.
• The sale of 3,651 shares was executed to cover tax withholding obligations related to the RSU vesting.
• This transaction was conducted under a Rule 10b5-1(c) plan, established on September 26, 2022.
• Following these transactions, Cecilia Jones beneficially owns 33,870 shares of common stock directly.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction (Form 4) reporting RSU vesting and a tax-related sale, which is a standard part of executive compensation and does not inherently indicate positive or negative sentiment about the company's performance or future prospects.

Positives

• The vesting of restricted stock units indicates continued compensation and retention of a key executive.
• The transaction was executed under a pre-arranged Rule 10b5-1(c) plan, demonstrating planned and compliant insider trading.

Negatives

• A portion of shares (3,651) was sold, which reduces the direct ownership stake of the CFO, although this was for tax purposes.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the general market risks associated with stock ownership.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance. It reports past transactions.

Industry Context

This is a routine insider transaction filing (Form 4) for a pharmaceutical company. It reflects standard executive compensation practices involving equity awards and subsequent tax-related sales, common across many industries, including biotech/pharma. It does not provide specific insights into broader industry trends.

Comparison to Industry Standards

• This is a standard Form 4 filing detailing an executive's equity transactions. The vesting of RSUs and subsequent sale to cover tax obligations is a common practice for executives across publicly traded companies, including peers in the biotechnology sector like Vertex Pharmaceuticals (VRTX) or Sarepta Therapeutics (SRPT).
• The specific number of shares or value is relative to the executive's compensation package and the company's stock price, not directly comparable as a performance metric against industry benchmarks.

Corporate Governance

Related Party Transactions

• The transaction involves an executive (Cecilia Jones) and the company's stock, which is a standard related party transaction in the context of executive compensation. No unusual related party dealings are noted.

Stakeholder Impact

• Shareholders: Minor dilution from RSU vesting (already accounted for in outstanding shares) and a slight reduction in direct insider ownership, but the transaction is routine and tax-driven.
• Employees: Reflects standard executive compensation practices, which can be a benchmark for other employees with equity awards.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing. The RSU vesting schedule indicates future vesting events on an annual basis.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations. Such transactions are common for executives and are typically pre-scheduled under Rule 10b5-1 plans, indicating no discretionary trading based on new material information. Therefore, this filing alone does not provide sufficient new information to warrant a change in investment recommendation; a 'hold' stance is appropriate as it reflects a neutral event.

Keywords

Agios Pharmaceuticals, AGIO, Cecilia Jones, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Sale, Tax Withholding, Rule 10b5-1